Frontiers at St Mark’s 2023: Navigating the complex and evolving treatment landscape in mCRC
Join Dr Kai-Keen Shiu, from UCLH, London, our symposium Chair, and other experts to review the dynamic and rapidly evolving treatment landscape in mCRC.
Dr Khurum Khan, from UCLH, London, provides a spotlight on Stivarga (regorafenib), bringing the regorafenib data into focus with RWE and clinical trial results, together with the targeted mode of action.
Dr Rille Pihlak, from Barts, London, discusses how to best maintain responses in advanced CRC after progression on IV chemotherapy.
Finally, Dr Shiu hosts an interactive Q & A session with a live and virtual audience at Frontiers.
This webinar is organised and funded by Bayer plc.
Speakers
Dr Kai-Keen Shiu
Dr Kai-Keen Shiu PhD FRCP is a Consultant in the Gastrointestinal Oncology Unit at University College London Hospital NHS Foundation Trust and Honorary Associate Professor at the UCL Cancer Institute. He is a Fellow of the Royal College of Physicians, London, and a member of ASCO, ESMO, and the Association of Cancer Physicians UK. His translational research interests include targeted treatments and immunotherapy for GI malignancies and carcinoma of unknown primary (CUP).
He is Chair of the NCRI MUO-CUP Workstream and a member of the NCRI Colorectal Advanced and Adjuvant Disease Subgroup. He is a collaborator in the PEACE (Posthumous tissuE donAtion in CancEr) study, and a member of the Gastrointestinal Oncology and CUP subgroups at UCL Cancer Institute/Francis Crick Institute. He is the Principal Investigator of the UCL/UCLH Gastrointestinal Cancer Translational Research Biobank.
Dr Khurum Khan
Dr Khurum Khan is a research-active consultant who remains at the forefront of cutting-edge research focusing on new targeted therapies in cancer, immunotherapy, and genomics. Leading gastrointestinal research at the Clinical Research Facility (CRF) at University College London Hospitals (UCLH) NHS Trust, his team has concentrated on druggable target discovery, and at UCL Cancer Institute, the team’s focus remains the discovery of biomarkers using liquid biopsies, patient-derived organoids (PDOs) and other novel technologies.
Dr Khan has led several research projects over the past few years, including the setup and conduct of large multicentre academic studies into advanced gastrointestinal cancers. As well as this, Dr Khan has written and published several high-impact research papers in peer-reviewed journals, and is the associate editor of the gastroenterology section of Frontiers in Oncology.
Dr Rille Pihlak
Dr Rille Pihlak MD PhD, has been a consultant medical oncologist at St Bart's Hospital in London since 2022. Outside of her current clinical role, she has various other international roles like being a member of the European Society for Medical Oncology (ESMO) Young Oncologist Committee and co-chair of the Postgraduate Medical Education Committee in The International Association for Medical Education (AMEE).
Report Adverse Events
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Bayer plc Tel: 01182 063 500, Fax: 01182 063 703, Email: pvuk@bayer.com.
If You Want to Report a Quality Complaint
Please report any quality complaint to Bayer Plc Email: qualitycomplaints@bayer.com For more information on how we process any personal data you share with us in relation to the above please see our Privacy Policy.
